IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3929
-0.0062 (-1.55%)
At close: Oct 13, 2025, 4:00 PM EDT
0.3950
+0.0021 (0.53%)
After-hours: Oct 13, 2025, 5:59 PM EDT

IGC Pharma Statistics

Total Valuation

IGC Pharma has a market cap or net worth of $36.13 million. The enterprise value is $36.45 million.

Market Cap36.13M
Enterprise Value 36.45M

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025, after market close.

Earnings Date Nov 11, 2025
Ex-Dividend Date n/a

Share Statistics

IGC Pharma has 91.96 million shares outstanding. The number of shares has increased by 23.99% in one year.

Current Share Class 91.96M
Shares Outstanding 91.96M
Shares Change (YoY) +23.99%
Shares Change (QoQ) +4.32%
Owned by Insiders (%) 8.36%
Owned by Institutions (%) 18.34%
Float 84.28M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 23.78
Forward PS n/a
PB Ratio 5.53
P/TBV Ratio 8.99
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 27.47
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.03.

Current Ratio 1.25
Quick Ratio 0.34
Debt / Equity 0.03
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -90.87% and return on invested capital (ROIC) is -60.16%.

Return on Equity (ROE) -90.87%
Return on Assets (ROA) -47.05%
Return on Invested Capital (ROIC) -60.16%
Return on Capital Employed (ROCE) -112.22%
Revenue Per Employee $18,957
Profits Per Employee -$90,600
Employee Count70
Asset Turnover 0.14
Inventory Turnover 0.50

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +7.51% in the last 52 weeks. The beta is 1.04, so IGC Pharma's price volatility has been similar to the market average.

Beta (5Y) 1.04
52-Week Price Change +7.51%
50-Day Moving Average 0.40
200-Day Moving Average 0.34
Relative Strength Index (RSI) 44.60
Average Volume (20 Days) 664,926

Short Selling Information

The latest short interest is 328,584, so 0.36% of the outstanding shares have been sold short.

Short Interest 328,584
Short Previous Month 905,970
Short % of Shares Out 0.36%
Short % of Float 0.39%
Short Ratio (days to cover) 0.46

Income Statement

In the last 12 months, IGC Pharma had revenue of $1.33 million and -$6.34 million in losses. Loss per share was -$0.08.

Revenue1.33M
Gross Profit 610,000
Operating Income -6.98M
Pretax Income -6.34M
Net Income -6.34M
EBITDA -6.38M
EBIT -6.98M
Loss Per Share -$0.08
Full Income Statement

Balance Sheet

The company has $454,000 in cash and $202,000 in debt, giving a net cash position of $252,000 or $0.00 per share.

Cash & Cash Equivalents 454,000
Total Debt 202,000
Net Cash 252,000
Net Cash Per Share $0.00
Equity (Book Value) 6.08M
Book Value Per Share 0.07
Working Capital 428,000
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$4.45 million and capital expenditures -$82,000, giving a free cash flow of -$4.53 million.

Operating Cash Flow -4.45M
Capital Expenditures -82,000
Free Cash Flow -4.53M
FCF Per Share -$0.05
Full Cash Flow Statement

Margins

Gross Margin 45.97%
Operating Margin -525.85%
Pretax Margin -477.92%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

IGC Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -23.99%
Shareholder Yield -23.99%
Earnings Yield -17.28%
FCF Yield -12.35%

Analyst Forecast

The average price target for IGC Pharma is $4.00, which is 918.07% higher than the current price. The consensus rating is "Strong Buy".

Price Target $4.00
Price Target Difference 918.07%
Analyst Consensus Strong Buy
Analyst Count 2
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on April 19, 2013. It was a reverse split with a ratio of 1:10.

Last Split Date Apr 19, 2013
Split Type Reverse
Split Ratio 1:10

Scores

IGC Pharma has an Altman Z-Score of -15.55 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -15.55
Piotroski F-Score 3